How Notoginsenoside R1 Helps Treat Diabetic Nephropathy
Author Information
Author(s): Li ChangYan, Geng Chen, Wang JiangMing, Shi Luyao, Ma JingYuan, Liang Zhang, Fan WenXing
Primary Institution: First Affiliated Hospital, Kunming Medical University
Hypothesis
Can notoginsenoside R1 reduce inflammation in diabetic nephropathy through its interaction with ITGB8?
Conclusion
Notoginsenoside R1 may help treat diabetic nephropathy by targeting the ITGB8 protein to reduce inflammation.
Supporting Evidence
- NGR1 treatment significantly improved blood glucose and kidney function markers in diabetic mice.
- ITGB8 expression was found to be lower in diabetic nephropathy patients compared to healthy individuals.
- NGR1 reduced podocyte inflammation and apoptosis in high glucose conditions.
Takeaway
This study found that a natural compound called notoginsenoside R1 can help protect kidneys from damage caused by diabetes by reducing inflammation.
Methodology
The study used network pharmacology, clinical correlation, and experimental validation to identify drug targets and assess the effects of NGR1 on diabetic nephropathy.
Participant Demographics
Patients aged between 50 and 80 years with diabetic nephropathy.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website